Storm Therapeutics
This clinical-stage biotechnology company develops small molecule therapeutics that target RNA modifying enzymes to treat cancer. Its lead candidate, STC-15, is a METTL3 inhibitor currently undergoing Phase 2 clinical trials for patients with select sarcomas. The platform focuses on RNA epigenetics to influence cellular decision-making and protein synthesis.
Visit websiteWaterbeach, UK
Biotechnology
Oncology
Life Sciences
Funding summary
- Total raised
- €75.7M
- Funding rounds
- 2
Investors in Storm Therapeutics
Investors on record for Storm Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Storm Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors